Leader in unlocking real-world data for healthcare moves to address the global evidence gap in markets plagued by tight data restrictions and a lack of clinical trial diversity

Atropos Health, a pioneer in evidence-based healthcare known for its Green Button Clinical Informatics Consult Service, today announced that it has completed a strategic financing from Presidio Ventures, the venture arm of Sumitomo Corporation Venture Group, Samsung Next, a venture arm of Samsung Electronics, Gaingels, Audere Capital, and others. The funding enables Atropos Health to accelerate commercial and development opportunities outside the U.S., using its proprietary technology and approach. Initial focus centers on key customers in Japan and Brazil.

“While the lack of representation in clinical trials creates an evidence gap for up to 70 percent of U.S patients, this effect is even more pronounced internationally. Lack of representation and relevant evidence on local populations leads to poorly informed treatment decisions and worse outcomes for patients around the world,” said Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health. “The support from our new strategic investors, Presidio and Samsung Next, and international healthcare partners underscores the value we deliver on a global scale– to unlock real-world data for evidence-based medicine.”

Atropos Health offers the world’s first award-winning platform for faster data evaluation, evidence generation and Generative AI innovation of research and care. This platform is designed to meet the demands of health systems and life science companies working to solve increasingly global, diverse and data-intensive healthcare problems. Atropos Evidence Platform is federated, allowing for compliance with sovereign policies on data retention, security, and privacy - such as General Data Protection Regulation, the standard of EU privacy law. This critical infrastructure opens up global research opportunities to accelerate evidence generation and representation.

Atropos Health’s cloud-based platform is uniquely able to navigate the data restrictions faced in international markets, providing vital data and insights to frontline physicians and researchers abroad. This is happening at a time when life-saving medical research is increasingly multinational, with more than half of all clinical trials taking place outside the US. Diversity in clinical trials is essential to advancing innovation of the best treatments for the right patients. Atropos’ unique global offerings help life science leaders overcome this challenge.

“Our investment in Atropos Health is a testament to our belief that this trailblazing team has the potential to revolutionize how health decisions are made, while saving both time and costs,” said Rameen Rana, Samsung Next. “Atropos Health is on track to make a profound impact on the healthcare industry, and we’re excited to be a part of their journey and look forward to the positive changes they will bring to healthcare worldwide.”

"The massive proliferation of patient data, coupled with advances in analytical methods, can enable providers and pharmaceutical companies to transform clinical decision-making, optimize drug development, and ultimately improve patient outcomes," said Tyler Schinto, Presidio Ventures. "We look forward to our strategic collaboration with Atropos Health to support the international expansion of its technology, which we believe will be at the forefront of the healthcare industry’s adoption of evidence-based informatics to enhance therapeutic results and lower the total cost of care."

With the additional capital and in-market support provided by Presidio and Samsung Next, Atropos Health is commencing engagements with several, international customers who will both add global RWD to their Atropos Evidence Platform and drive new RWD in the Atropos Evidence Library. Providers and researchers outside the U.S. can begin to generate evidence-based insights through Atropos Green Button service. In addition to the strategic investment, Atropos Health has added partnerships with Analitica, Syndesis Health, DVX, and Project 360 LTD, to provide a critical footprint of in-market data integration support and channel distribution across Asia, South America and the Middle East.

About Atropos Health

Atropos Health is the developer of Atropos Evidence™ Platform, a catalyst for evidence generation from a network of real world data. Healthcare organizations, life science companies, and other clinicians and researchers leverage our platform to close evidence gaps from bench to bedside, elevate clinical outcomes with data-driven care, expedite research, and more. Atropos Health’s offerings are based upon dozens of peer-reviewed publications, thousands of clinician users, a decade of clinical use, and clinical expertise. We aim to transform healthcare with timely, relevant real-world evidence.

To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or follow on Twitter @AtroposHealth.

About Presidio Ventures & Sumitomo Corporation

Presidio Ventures is the VC arm of Sumitomo Corporation, a leading Fortune 500 global diversified trading and business investment company with 129 locations (Japan: 20, Overseas: 109) in 66 countries and regions. As an investor and a partner, Presidio Ventures assists early-stage technology, internet, mobile, media and cleantech companies looking towards global markets, like Japan and Asia, to grow their business and maintain their competitive edge. Presidio leverages its technological expertise, international business development experience, and a cross-industry network to identify overseas partners for its portfolio companies and provides financial resources necessary to take advantage of growth opportunities. Presidio Ventures is a subsidiary of Sumitomo Corporation and has offices in Silicon Valley, Boston, and Los Angeles.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230921925336/en/